Insider · CIK 0001887865
Amy Sullivan
Files at IOBT (IO Biotech, Inc.). First filing Dec 23, 2024, latest Dec 23, 2024.
In brief
Amy Sullivan files SEC Form 4 as CFO at IOBT (IO Biotech, Inc.). Since Dec 23, 2024, Amy Sullivan has reported 1 open-market buy worth $8,483 and 0 open-market sells worth $0, the latest filed on Dec 23, 2024.
A track record needs three past buys with six months of prices behind them; Amy Sullivan has 0, so none is measured yet.
The newest scored trade: bought $8,483 of IOBT on Dec 23, 2024, filed Dec 23, 2024, scored 40 (moderate).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | IO Biotech, Inc. | $8,483 10,250 shares | +14% | - |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 2, 2025 | IOBT IO Biotech, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +215,000 | $0.00 | $0 | 215,000 | Apr 4, 2025 |
| Dec 23, 2024 | IOBT IO Biotech, Inc. | POpen-market purchase Common Stock | +10,250 | $0.83 | $8,483 | 84,632 | Dec 23, 2024 |
| Mar 15, 2024 | IOBT IO Biotech, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +280,000 | $0.00 | $0 | 280,000 | Mar 18, 2024 |
Questions about Amy Sullivan
Answered from the filings on this page, as of the latest one.
Is Amy Sullivan buying or selling?
Not in the last 12 months. Amy Sullivan's latest open-market trade on SEC Form 4 was bought $8,483 of IOBT on Dec 23, 2024.
How did Amy Sullivan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Amy Sullivan has 0.
Where does Amy Sullivan file Form 4?
Amy Sullivan has filed Form 4 at IOBT (IO Biotech, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.